Yes,the latest issue of the new england medical journal highlights a new drug GDC-0449 in clinical trials which blocks the so called hedgehog signiling pathway which is activated during a wide range of cancers.It is belived that blocking this pathway could yield a greater degree of selectivity and as a result produce less sideeffects.
For details on the study buy the lastest issue of the new england medical journal.
Its always good that to see new treatments that take into account sideeffects.....
Reference
new england medical journal, septemter 17 2009
No comments:
Post a Comment